Cargando…

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Antonio, Obici, Laura, Cattalini, Marco, Lopalco, Giuseppe, Merlini, Giampaolo, Ricco, Nicola, Soriano, Alessandra, La Torre, Francesco, Verrecchia, Elena, Insalaco, Antonella, Dagna, Lorenzo, Jaber, Masen Abdel, Montin, Davide, Emmi, Giacomo, Ciarcia, Luisa, Barneschi, Sara, Parronchi, Paola, Ruscitti, Piero, Maggio, Maria Cristina, Viapiana, Ombretta, Sota, Jurgen, Gaggiano, Carla, Giacomelli, Roberto, Sicignano, Ludovico Luca, Manna, Raffaele, Renieri, Alessandra, Lo Rizzo, Caterina, Frediani, Bruno, Rigante, Donato, Cantarini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295690/
https://www.ncbi.nlm.nih.gov/pubmed/34307404
http://dx.doi.org/10.3389/fmed.2021.668173
_version_ 1783725486647541760
author Vitale, Antonio
Obici, Laura
Cattalini, Marco
Lopalco, Giuseppe
Merlini, Giampaolo
Ricco, Nicola
Soriano, Alessandra
La Torre, Francesco
Verrecchia, Elena
Insalaco, Antonella
Dagna, Lorenzo
Jaber, Masen Abdel
Montin, Davide
Emmi, Giacomo
Ciarcia, Luisa
Barneschi, Sara
Parronchi, Paola
Ruscitti, Piero
Maggio, Maria Cristina
Viapiana, Ombretta
Sota, Jurgen
Gaggiano, Carla
Giacomelli, Roberto
Sicignano, Ludovico Luca
Manna, Raffaele
Renieri, Alessandra
Lo Rizzo, Caterina
Frediani, Bruno
Rigante, Donato
Cantarini, Luca
author_facet Vitale, Antonio
Obici, Laura
Cattalini, Marco
Lopalco, Giuseppe
Merlini, Giampaolo
Ricco, Nicola
Soriano, Alessandra
La Torre, Francesco
Verrecchia, Elena
Insalaco, Antonella
Dagna, Lorenzo
Jaber, Masen Abdel
Montin, Davide
Emmi, Giacomo
Ciarcia, Luisa
Barneschi, Sara
Parronchi, Paola
Ruscitti, Piero
Maggio, Maria Cristina
Viapiana, Ombretta
Sota, Jurgen
Gaggiano, Carla
Giacomelli, Roberto
Sicignano, Ludovico Luca
Manna, Raffaele
Renieri, Alessandra
Lo Rizzo, Caterina
Frediani, Bruno
Rigante, Donato
Cantarini, Luca
author_sort Vitale, Antonio
collection PubMed
description Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbations was 458.2 flare/100 patients-year during the 12 months prior to the start of biologic treatment and 65.7 flare/100 patients-years during the first 12 months of therapy (p < 0.0001). The median duration of attacks was 5.00 (IQR = 10.50) days at the start of biologics and 1.00 (IQR = 0.00) days at the 12-month assessment (p < 0.0001). Likewise, a significant reduction was observed in the Autoinflammatory Disease Activity Index during the study period (p < 0.0001). A significant corticosteroid sparing effect was observed as early as the first 12 months of treatment both in the number of patients requiring corticosteroids (p = 0.025) and in the dosages employed (p < 0.0001). A significant reduction was identified in the erythrocyte sedimentation rate (p < 0.0001), C reactive protein (p < 0.0001), serum amyloid A (p < 0.0001), and in the 24-h proteinuria dosage during follow-up (p = 0.001). A relapsing-remitting disease course (OR = 0.027, C.I. 0.001–0.841, p = 0.040) and the frequency of relapses at the start of biologics (OR = 0.363, C.I. 0.301–0.953, p = 0.034) were significantly associated with a complete response. No serious adverse events were observed. Conclusions: Treatment with biologic agents is highly effective in controlling clinical and laboratory TRAPS manifestations. Patients with a relapsing-remitting course and a lower frequency of flares at the start of treatment show more likely a complete response to biologic agents.
format Online
Article
Text
id pubmed-8295690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82956902021-07-23 Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network Vitale, Antonio Obici, Laura Cattalini, Marco Lopalco, Giuseppe Merlini, Giampaolo Ricco, Nicola Soriano, Alessandra La Torre, Francesco Verrecchia, Elena Insalaco, Antonella Dagna, Lorenzo Jaber, Masen Abdel Montin, Davide Emmi, Giacomo Ciarcia, Luisa Barneschi, Sara Parronchi, Paola Ruscitti, Piero Maggio, Maria Cristina Viapiana, Ombretta Sota, Jurgen Gaggiano, Carla Giacomelli, Roberto Sicignano, Ludovico Luca Manna, Raffaele Renieri, Alessandra Lo Rizzo, Caterina Frediani, Bruno Rigante, Donato Cantarini, Luca Front Med (Lausanne) Medicine Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbations was 458.2 flare/100 patients-year during the 12 months prior to the start of biologic treatment and 65.7 flare/100 patients-years during the first 12 months of therapy (p < 0.0001). The median duration of attacks was 5.00 (IQR = 10.50) days at the start of biologics and 1.00 (IQR = 0.00) days at the 12-month assessment (p < 0.0001). Likewise, a significant reduction was observed in the Autoinflammatory Disease Activity Index during the study period (p < 0.0001). A significant corticosteroid sparing effect was observed as early as the first 12 months of treatment both in the number of patients requiring corticosteroids (p = 0.025) and in the dosages employed (p < 0.0001). A significant reduction was identified in the erythrocyte sedimentation rate (p < 0.0001), C reactive protein (p < 0.0001), serum amyloid A (p < 0.0001), and in the 24-h proteinuria dosage during follow-up (p = 0.001). A relapsing-remitting disease course (OR = 0.027, C.I. 0.001–0.841, p = 0.040) and the frequency of relapses at the start of biologics (OR = 0.363, C.I. 0.301–0.953, p = 0.034) were significantly associated with a complete response. No serious adverse events were observed. Conclusions: Treatment with biologic agents is highly effective in controlling clinical and laboratory TRAPS manifestations. Patients with a relapsing-remitting course and a lower frequency of flares at the start of treatment show more likely a complete response to biologic agents. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8295690/ /pubmed/34307404 http://dx.doi.org/10.3389/fmed.2021.668173 Text en Copyright © 2021 Vitale, Obici, Cattalini, Lopalco, Merlini, Ricco, Soriano, La Torre, Verrecchia, Insalaco, Dagna, Jaber, Montin, Emmi, Ciarcia, Barneschi, Parronchi, Ruscitti, Maggio, Viapiana, Sota, Gaggiano, Giacomelli, Sicignano, Manna, Renieri, Lo Rizzo, Frediani, Rigante and Cantarini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Vitale, Antonio
Obici, Laura
Cattalini, Marco
Lopalco, Giuseppe
Merlini, Giampaolo
Ricco, Nicola
Soriano, Alessandra
La Torre, Francesco
Verrecchia, Elena
Insalaco, Antonella
Dagna, Lorenzo
Jaber, Masen Abdel
Montin, Davide
Emmi, Giacomo
Ciarcia, Luisa
Barneschi, Sara
Parronchi, Paola
Ruscitti, Piero
Maggio, Maria Cristina
Viapiana, Ombretta
Sota, Jurgen
Gaggiano, Carla
Giacomelli, Roberto
Sicignano, Ludovico Luca
Manna, Raffaele
Renieri, Alessandra
Lo Rizzo, Caterina
Frediani, Bruno
Rigante, Donato
Cantarini, Luca
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title_full Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title_fullStr Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title_full_unstemmed Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title_short Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
title_sort biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome—therapeutic outcome and predictors of response: real-life data from the aida network
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295690/
https://www.ncbi.nlm.nih.gov/pubmed/34307404
http://dx.doi.org/10.3389/fmed.2021.668173
work_keys_str_mv AT vitaleantonio biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT obicilaura biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT cattalinimarco biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT lopalcogiuseppe biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT merlinigiampaolo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT ricconicola biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT sorianoalessandra biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT latorrefrancesco biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT verrecchiaelena biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT insalacoantonella biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT dagnalorenzo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT jabermasenabdel biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT montindavide biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT emmigiacomo biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT ciarcialuisa biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT barneschisara biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT parronchipaola biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT ruscittipiero biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT maggiomariacristina biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT viapianaombretta biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT sotajurgen biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT gaggianocarla biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT giacomelliroberto biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT sicignanoludovicoluca biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT mannaraffaele biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT renierialessandra biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT lorizzocaterina biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT fredianibruno biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT rigantedonato biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork
AT cantariniluca biotechnologicalagentsforpatientswithtumornecrosisfactorreceptorassociatedperiodicsyndrometherapeuticoutcomeandpredictorsofresponsereallifedatafromtheaidanetwork